Rexulti Works for Agitation in Alzheimer's, Despite Risks, Says FDA Staff

Increased mortality risk consistent with other antipsychotics in elderly dementia patients

First FDA Approved Medication for Agitation Associated with Alzheimer's Dementia – Psychiatry Education Forum

SLU Researcher Finds Help for Alzheimer's-Associated Agitation with New FDA-Approved Treatment : SLU

Alzheimer's drug controversies and scandals: behind closed doors

First-Ever Drug for Alzheimer's Agitation, Brexpiprazole, Nears Finish Line

REXULTI® (brexpiprazole) Agitation associated with dementia due to Alzheimer's disease

FDA approves Rexulti for agitation tied to Alzheimer's dementia, Daily therapy is first to be approved for this use in US

STOP Treating Behaviors with Restraining Medications - Positive Approach to Care

FDA fast-tracking approval of new drugs — fewer trials, less info

Brexpiprazole (Rexulti) Approved for Alzheimer's Agitation

Otsuka, Lundbeck's sNDA for Rexulti received US FDA approval

BioXcel: Treatment For Agitation In Alzheimer's: Multi-Billion Opportunity

Brexpiprazole (Rexulti) Approved for Alzheimer's Agitation

Controversy Surrounds Brexpiprazole's FDA Approval, a New Alzheimer's Agitation Drug

Treatments for Behavior Alzheimer's Association